key: cord-0834685-ry6xr4ix authors: Yamashita, Masamichi title: Aspirin Intolerance: Experimental Models for Bed-to-Bench date: 2016-12-03 journal: Curr Drug Targets DOI: 10.2174/1389450117666161005152327 sha: a40363fa5527e9b6dbf6930b247a4608027e7983 doc_id: 834685 cord_uid: ry6xr4ix Aspirin is the oldest non-steroidal anti-inflammatory drug (NSAID), and it sometimes causes asthma-like symptoms known as aspirin-exacerbated respiratory disease (AERD), which can be serious. Unwanted effects of aspirin (aspirin intolerance) are also observed in patients with food-dependent exercise-induced anaphylaxis, a type I allergy disease, and aspirin-induced urticaria (AIU). However the target and the mechanism of the aspirin intolerance are still unknown. There is no animal or cellular model of AERD, because its pathophysiological mechanism is still unknown, but it is thought that inhibition of cyclooxygenase by causative agents leads to an increase of free arachidonic acid, which is metabolized into cysteinyl leukotrienes (cysLTs) that provoke airway smooth muscle constriction and asthma symptoms. As the bed-to-bench approach, to confirm the clinical discussion in experimental cellular models, we have tried to develop a cellular model of AERD using activated RBL-2H3 cells, a rat mast cell like cell line. Indomethacin (another NSAID and also causes AERD), enhances in vitro cysLTs production by RBL-2H3 cells, while there is no induction of cysLTs production in the absence of inflammatory activation. Since this suggests that all inflammatory cells with activation of prostaglandin and cysLT metabolism should respond to NSAIDs, and then I have concluded that aspirin intolerance should be separated from subsequent bronchoconstriction. Evidence about the cellular mechanisms of NSAIDs may be employed for development of in vitro AERD models as the approach from bench-to-bed. According to the asthma guideline of the US National Heart, Lung and Blood Institute, 21% of adult asthma patients and 5% of pediatric asthma patients have AERD [8] , while the Japanese asthma guideline [9] states that 5-10% of adult asthma patients and 3.6-7.8% of pediatric asthma patients have AERD. According to both guidelines, the majority of AERD patients are adults. Females are affected twice as often as males, but other factors such as the family history, ethnicity, or geographic region have no influence [10] , suggesting that genetic disorders are not related to the pathogenesis of AERD. Nasal polyps and dysosmia are frequent in AERD patients [9, 11, 12] . Asthma attacks triggered by aspirin intolerance can be serious, and it was reported that 40% of patients receiving emergency treatment for asthma have AERD [13, 14] . Since AERD has been reported in patients without known prior exposure to the triggering compound, it seems that the underlying mechanism is not type I allergy [10] . Evidence shows that treatment with chromoglycate is effective for AERD [15] , suggesting that mast cells may play a pivotal role in this condition. Aspirin intolerance is also observed in a condition called aspirin-induced urticaria (AIU), in which urticaria and/or angioedema develops at 1-6 h after exposure to COX-1inhibiting NSAIDs in 12% of patients with chronic urticaria [16] [17] [18] . AERD and AIU account for the majority of patients with aspirin intolerance. Harada et al. [19] reported that aspirin intolerance was observed in all of their patients with food-dependent exercise-induced anaphylaxis (FDEIA), a condition combining food allergy and respiratory disorder that is mostly related to wheat or crustaceans. FDEIA differs from AERD, since many patients are teenage boys and 40% of them have atopic diseases, suggesting that FDEIA is associated with type I allergy. While 10% of patients develop asthma attacks with exercise several hours after intake of a causative food, they have no symptoms if they do not exercise [20] . These differences between AERD and FDEIA may indicate that the type of allergy (atopic or non-atopic) is not important, or may suggest that non-atopic immune activation underlies the atopic characteristics of FDEIA. Accordingly, it is possible that aspirin intolerance should be separated from the subsequent bronchoconstriction in AERD or FDEIA. As shown in Fig. (2) , the enzyme phospholipase A 2 releases fatty acids from cell membrane phospholipids. Arachidonic acid is one of the fatty acids released and it is metabolized into various substances, including prostaglandins (PGs), leukotrienes (LTs), and thromboxanes (TXs), which are thought to make a major contribution to the pathogenesis of inflammatory diseases. PGD 2 and PGE 2 are arachidonic acid metabolites produced by cyclooxygenase (COX, also called prostaglandin G/H synthase, PGHS, EC 1.14.99.1) which metabolizes ara-chidonic acid to PGG 2 by its cyclooxygenase activity and then metabolizes PGG 2 to PGH 2 by its hydroperoxidase activity (Fig. 2) . Metabolites of COX are known to contribute to inflammation. In 1990s, two subtypes of the COX enzyme were found. One of these was named COX-1 and was found to be constitutively expressed by cells. The other was named COX-2 [21, 22] , and this was found to be induced by physiological and experimental inflammatory stimuli, such as the carcinogenic promoter 12-O-tetradecanoylphorbol 13acetate thapsigargin, or calcium ionophore A23187 [23] [24] [25] [26] . Transcription of COX-2 protein is controlled by various transcription factors, including nuclear factor-κB (NF-κB) and AP-1 [27] [28] [29] [30] [31] , via degradation of the inhibitory protein, IκB [32] . Specific COX-2 inhibitors were developed to avoid the side effect of gastrointestinal ulceration, and it was revealed that selectivity is due to difference of tertiary protein structure between COX-1 and COX-2 [33] [34] [35] [36] . Arachidonic acid is also metabolized to leukotriene A 4 (LTA 4 ) by another pathway involving 5-lipoxygenase (5-LOX), after which LTA 4 is converted to LTB 4 and LTC 4 . Then LTC 4 is metabolized to LTD 4 , and LTE 4 as shown in Fig. (2) . LTC 4 , LTD 4 , and E 4 contain cysteine residues, and thus are called cysteinyl leukotrienes (cysLTs). Cysteinyl LTs were originally discovered as slow reacting substance of anaphylaxis (SRS-A), which was extracted from the lung tissues of antigen-sensitized guinea pigs, and was shown to constrict airway smooth muscle from these animals more potently, slowly, and continuously than histamine via an antihistamine-resistant mechanism [37] . Urinary concentrations of cysLTs are elevated in AERD patients, even when they have no asthma symptoms [38] , and cysLT inhibitors, such as 5-LOX inhibitor [39] , or cysLT receptor blockers [40] [41] [42] are reported to be safe and effective for AERD, indicating involvement of cysLTs in the mechanism underlying this disease. Aspirin is an anti-inflammatory analgesic agent that has been marketed since 1899 and is the oldest chemically syn- thesized drug (Fig. 1a) . In the 1970s, it was found that the mechanism of action of aspirin and other acidic NSAIDs involves inhibition of PG production [43] [44] [45] . In the 1990s, the molecular mechanism of aspirin was finally revealed to be irreversible acetylation of Ser-530 on COX [46] , with inhibition of both COX-1 and COX-2 [23] , while most NSAIDs such as indomethacin (Fig. 1b) reversibly inhibit COX. Almost all (80-100%) the oral dose of aspirin (100-300 mg) is immediately absorbed from the stomach or upper small intestine and the maximum serum concentration is reached within 35 min. Then it is metabolized into salicylic acid ( Fig. 3a) and conjugated with a glucuronate or sulfate. A sodium salt of the one of the metabolites, gentisic acid ( Fig. 3b) , is reported to have an anti-inflammatory effect [47] . Interestingly, selective COX-2 inhibitors have been reported to be safe for AERD patients [48] [49] [50] [51] , indicating the pivotal involvement of COX-1 in the mechanism of AERD. In 1990s, it was hypothesized that suppression of prostaglandin production via inhibition of COX leads to accumulation of excess arachidonic acid both inside and outside of cells, after which the excess arachidonic acid is metabolized into cysLTs that cause asthma attacks [38, [52] [53] [54] [55] . The pathogenic mechanism of AERD is still not clear. Most of the research performed has been clinical because useful animal or cellular models do not exist. Some attempts to develop experimental models of AERD are ongoing based on clinical information. We have tried to develop a cellular model of AERD based on inhibition PG production by NSAIDs, and we pre-viously assessed the effect on cysLT production in the RBL-2H3 mast cell line derived from rat basophilic leukemia [56] . We choose indomethacin (≦3 µM, Fig. 1b) as the NSAID to avoid unexpected protein acetylation by using aspirin [57] . We found that cysLT production increased when RBL-2H3 cells were pretreated overnight with dinitrophenol (DNP)specific immunoglobulin E (IgE) and then treated with DNPconjugated human serum albumin, creating a cellular model of type I allergy [58] [59] [60] . Treatment with indomethacin at concentration up to 3 μM did not cause dose-dependent changes of cysLT production, while there was almost 90% inhibition of PGD 2 production. LTB 4 production was significantly increased by indomethacin at 1-3 μM. Our observation regarding LTB 4 is supported by a study of Planaguma et al. [61] using rat Kupffer cells; adding aspirin (up to 5 mM) doubled LTB 4 production while inhibiting PGE 2 production approximately 60%. Then we tried adding arachidonic acid (1-10 μM) with DNP-HSA to the culture medium of RBL-2H3 cells. Cysteinyl LT production was significantly increased by adding arachidonic acid combined with allergic stimulation, while there was no significant change without allergic stimulation [57] . As mentioned above, AERD is not thought to be a type I allergic disease, so we also tested non-allergic stimulation of RBL-2H3 cells with calcium ionophore A23187 and obtained the similar results. Our observations indicate that induction of cysLT production by indomethacin may require some inflammatory stimulation of mast cells. If AERD is fundamentally a prob- In our experiments described above [57] , we obtained the interesting result that 0.1 μM of indomethacin slightly, but significantly increased the production of LTC 4 , and LTE 4 . We also tested indomethacin from another source to avoid the influence of contamination by other factors, and the same result was observed. Togo et al. [62] reported that aspirin and salicylate (both at 100-300 μM) increased LTC 4 production by the RBL-2H3 mast cell line and mouse bone marrow-derived mast cells, and suggested that the mechanism involved calcium influx following activation of cytosolic phospholipase A 2 . We cannot conclude whether their observation corresponds with ours or not, and it is also unclear whether the effect of these NSAIDs is related to AERD. Liu et al. [63] studied mice with knockout of microsomal PGE synthase-1 (mPGES-1), which associates with COX-2 and metabolizes PGH 2 to PGE 2 (Fig. 2) . After pretreatment with dust mite extract and challenge with lysine-aspirin (1.2 mg/12 µL via a ventilator), there was a marked increase of respiratory tract resistance and elevation of the levels of cysLTs, histamine, and MCP-1 (an indicator of mast cell degranulation) in bronchoalveolar lavage fluid. Ketorolac (a selective COX-1 inhibitor) and celecoxib (a selective COX-2 inhibitor) failed to increase respiratory tract resistance in this model. However, an EP2 receptor agonist significantly inhibited these responses, and EP2 receptor knockout mice showed smaller increases than mPGES-1 knockout mice. They recently observed that interleukin (IL)-33, a type 2 helper T (Th2) cytokine released from necrotic cells as "alarmin" [64] , was highly expressed in the lung epithelium of mPGES-1 knockout mice pretreated with mite extract and in the nasal polyps of AERD patients [65, 66] . It was reported that IL-33 is produced by mast cells and that it increases the production of IL-4, IL-5, and IL-6 by bone marrow-derived murine mast cells and a murine mast cell line (MC/9) when these cells received IgE sensitization followed by antigen treatment. It was also reported that the IL-33 receptor (ST-2) is expressed by mast cells after atopic stimulation [67] . Another class of ST-2 positive memory-type Th2 cells, known as pathogenic Th2 cells, was recently proposed to have a role in inflammatory diseases including asthma [68] . Though the relationship between the pathogenic Th2 cells and AERD is unclear, T cells or their cytokines could activate mast cells in AERD patients. The observation that mPGES knockout mice respond to lysine-aspirin [63] may indicate that inhibition of cytosolic PGES (cPGES) associated with COX-1 (Fig. 4) could be at least partly involved in AERD, suggesting that cPGES activators could be effective for this condition. Nakatani et al. [69] studied the effect of cPGES knockout, and reported that cPGES-null mice undergo perinatal death with low body weight, hypoplastic skin changes, and alveolar collapse in the lungs at 18.5 days post-coitum. In contrast, heterozygous knockout mice seemed normal, apart from the cPGES protein level. They did not provide information about the effect of NSAIDs on cPGES heterozygous knockout animals. We previously observed that auranofin, a gold compound for rheumatoid arthritis, induced a COX-1-dependent increase of PGE 2 production without significant induction of COX-1 protein within 4 h after inflammatory treatment of rat peritoneal macrophages, while nitric oxide production was not increased [25, 26, 31] . It was also reported that auranofin induces p23, a co-chaperone of heat shock protein 90 that was later identified as cPGES (Fig. 2) [70] . If reduction of PG synthesis via cPGES/COX-1 plays an important role in AERD, auranofin or other cPGES activator(s) could be effective for this condition. Findings in our cellular model suggested that mast cells may require inflammatory activation for overproduction of cysLTs with COX inhibition. Some classes of T cells and some cytokines may be involved the pathogenesis of AERD by activating mast cells. Therefore, in vitro experiments may be able to identify inflammatory mediators that activate mast cells and PGES activators, with the results having clinical implications. The mechanism through which NSAIDs act on COX is very clear and explains many inflammatory phenomena, but we could not explain all the effects of NSAIDs through inhibition of COX activity. As described above, some causative substances of AERD may not strongly inhibit COX-1-dependent PG synthesis. We previously observed that the ligands of two well-known nuclear receptors, peroxisome proliferator-activated receptor (PPAR) α and γ, independently reduced cysLT release from stimulated RBL-2H3 mast cell line [58] [59] [60] . This may suggest the possibility of a role of some unknown target(s) of NSAIDs and other causative substances. Aspirin is reported to be associated with phospholipase A 2 [71] , which is the enzyme that liberates arachidonic acid from membrane phospholipids (Fig. 2) . Aspirin and other NSAIDs are also reported to affect various mitochondrial enzyme complexes, including NADHubiquinone oxidoreductase (complex I), succinate dehydrogenase (complex II), cytochrome bc 1 complex (complex III) and cytochrome c oxidase (complex IV) [72, 73] . Antimycin, a specific complex III inhibitor, is reported to inhibit histamine release from experimentally stimulated human mast cells obtained by bronchoalveolar lavage [74] . Antimycin was also reported to increase reactive oxygen species in the mitochondria of a pollen extract-treated A549 human alveolar epithelial cell line and the authors suggested that damage to mitochondrial respiration-related proteins may exacerbate inflammation [75] . I found that the amino acid sequence of the acetylated by aspirin in COX (FSLKG from 529 to 533) [46] , is also in the primary protein structure [76] of human corona virus HKU1 near the nonstructural protein (nsp) 4 domain which has a similar amino acid alignment to nsp4 of murine hepatitis virus. I could not find a nomenclature for this 5 amino acid site in HKU1, and I cannot predict whether aspirin and other NSAIDs act via this site in humans. Salicylic acid (Fig. 1f) is secreted by plants in response to pathogens and induces resistance to viruses [77] . The salicylate receptors in plants are nonexpressors of PR gene 1 (NPR1), which is a homolog of IκB in mammals [78] , and has NPR1-like proteins 3, and 4 as paralogues [79, 80] . In tumor necrosis factor-treated COS-1 cells, it has been demonstrated that sodium salicylate (1-20 mM) inhibits the degradation of IκBα, but not IκBβ, via inhibition of IκB kinase activity [81, 82] . Recently, Honjo et al. reported the discovery of 36 genes related to thermal nociception in Drosophila larvae [83] . Twenty of 36 genes have human orthologs, and some of them are not known to be related to pain sensation. This is interesting because pain sensation in the respiratory tract may be related to cough in asthma patients. PGE 2 is known to enhance pain, which is why NSAIDs are analgesics. It is possible that PGE 2 or aspirin acts directly or indirectly on these gene products to enhance nociceptive sensation in inflammation. In traditional Japanese medicine, a disease with a high risk of occurrence in the future, is called "mibyou" [84, 85] . I think that AERD patients who have never experienced an asthma attack could be considered as "mibyou" patients. While asthma attacks associated with AERD are frequently serious, we cannot define whether a person is at risk of AERD or not until asthma occurs following the intake of a causative substance. If we could determine the mechanism of AERD and identify the risk of asthma during the "mibyou" period, we could prevent AERD and reduce the number of asthma deaths. Further clinical investigations of AERD are needed, and additional basic studies based on the clinical information could also help clinicians to understand the pathophysiological features of this disease. The author confirm that this article content has no conflict of interest. Concerning the nature of intolerance to aspirin First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)-1922 (with a note on aspirin desensitization). By F. Widal, P. Abrami Anaphylaxie et idiosyncrasie. La presse médicale 1922 Bronchial asthma induced by indomethacin Aspirin and other salicylates 1992 Natural salicylates: foods, functions and disease prevention Young IS. Dietary salicylates Guidelines for the diagnosis and management of asthma. National Heart Lung and Blood Institute Japanese Society of Allegology. Asthma prevention and management guideline Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions The natural history and clinical characteristics of aspirin-exacerbated respiratory disease Aspirin and concomitant idiosyncrasies in adult asthmatic patients Contribution of aspirinintolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture Sodium cromoglycate nebulized solution has an acute bronchodilative effect in patient with aspirin-intolerant asthma (AIA) Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients Aspirin-exacerbated diseases: Advances in asthma with nasal polyposis, urticaria, angioedema, and anaphylaxis Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria A study of food-dependent exercise-induced anaphylaxis by analyzing the Japanese cases reported in the literature 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages Inhibition by auranofin of the production of prostaglandin E2 and nitric oxide in rat peritoneal macrophages Induction of nitric oxide synthase by lipopolysaccharide and its inhibition by auranofin in RAW 264.7 cells Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages NF-κB involvement in IL-1β-induction of GM-CSF and COX-2: inhibition by glucocorticoids does not require I-κB Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes Inducibility of κ immunoglobulin enhancerbinding protein NF-κB by a posttranslational mechanism Inhibition of TPAinduced NF-κB nuclear translocation and production of NO and PGE2 by the anti-rheumatic gold compounds Effects of chrisotherapeutic gold compounds on prostaglandin E2 production HIV1 infection of human monocytes and macrophages promotes induction or translocation of NF-KB-related factors Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirinsensitive asthma Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist Montelukast is only partially effective in inhibiting aspirin responses in aspirinsensitive asthmatics Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078 Indomethacin and aspirin abolish prostaglandin release from the spleen Aspirin selectively inhibits prostaglandin production in human platelets Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Prostaglandin endoperoxide synthase. The aspirin acetylation region The estimation of sodium genistate in tablets and injections Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) -classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials Safety of a specific COX-2 inhibitor in aspirin-induced asthma The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors Increased excretion of leukotriene E4 during aspirin-induced asthma Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma Inhibition of IgE-mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation Effects of the inhibition of prostaglandin production on leukotriene production in rat mast cell line RBL-2H3 Peroxisome proliferator-activated receptor αindependent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells PPARα/γ-independent effects of PPARα/γ ligands on cysteinyl leukotriene production in mast cells Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4 Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca 2+ influx Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes Role of IL-33 in inflammation and disease Aspirin-exacerbated respiratory diseasenew prime suspects Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway IL-33 is produced by mast cells and regulates IgE-dependent inflammation CD4 + T cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: Crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 Å resolution Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells Inhibition of mitochondrial complex I by various non-steroidal antiinflammatory drugs and its protection by quercetin via a coenzyme Q-like action Further characterisation of substance P induced histamine release from human bronchoalveolar lavage mast cells Mitochondrial dysfunction increases allergic airway inflammation Reveals a Novel Genotype and Evidence of Natural Recombination in Coronavirus HKU1 Acetylsalicylic acid (aspirin) induces resistance to tobacco mosaic virus in tobacco Systemic acquired resistance Systemic acquired resistance: turning local infection into global defense NPR3 and NPR4 are receptors for the immune signal salicylic acid in plants Inhibition of IκB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β Nociceptor-enriched genes required for normal thermal nociception Mibyo (preventive medicine) in aged society The concept of Mibyou and the need of its treatment for the coming advanced aged society-in order to prevention for nursing and care I wish to thank Dr. Hiroko Watanabe (Kanagawa Prefectural Institute of Public Health) whose lecture on 14 May 2014, proposed the similarity between FDEIA and AERD, and Dr. Kiyoshi Hirahara (Chiba University) whose lecture on 6 October 2015, suggested involvement of IL-33 in nonallergic asthma including AERD.